End-of-day quote
Norwegian OTC
06:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
41
NOK
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
89.83
|
85.91
|
100.8
|
188.9
|
188.9
|
203.8
|
Enterprise Value (EV)
1 |
-50.2
|
59.27
|
32.06
|
74.94
|
30.16
|
-52.97
|
P/E ratio
|
3.78
x
|
-0.85
x
|
2.49
x
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
15.8%
|
-
|
-
|
Capitalization / Revenue
|
1.44
x
|
5.1
x
|
1.2
x
|
0.4
x
|
1.36
x
|
1.59
x
|
EV / Revenue
|
-0.8
x
|
3.52
x
|
0.38
x
|
0.16
x
|
0.22
x
|
-0.41
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1.4
x
|
-38.2
x
|
0.62
x
|
0.23
x
|
0.6
x
|
-0.72
x
|
FCF Yield
|
-71.5%
|
-2.62%
|
160%
|
426%
|
166%
|
-138%
|
Price to Book
|
0.5
x
|
1.3
x
|
0.92
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,990
|
4,773
|
5,040
|
4,971
|
4,971
|
4,971
|
Reference price
2 |
18.00
|
18.00
|
20.00
|
38.00
|
38.00
|
41.00
|
Announcement Date
|
6/14/18
|
6/21/19
|
6/25/20
|
6/21/21
|
6/16/22
|
11/1/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
62.38
|
16.83
|
83.94
|
469.1
|
139.3
|
128
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
60.73
|
14.82
|
82
|
467
|
135.7
|
125.7
|
Operating Margin
|
97.35%
|
88.04%
|
97.69%
|
99.56%
|
97.37%
|
98.21%
|
Earnings before Tax (EBT)
1 |
22.74
|
-107.3
|
39.93
|
427.7
|
82.14
|
100.2
|
Net income
1 |
22.74
|
-107.3
|
39.93
|
427.7
|
82.14
|
100.2
|
Net margin
|
36.45%
|
-637.3%
|
47.57%
|
91.17%
|
58.96%
|
78.33%
|
EPS
2 |
4.764
|
-21.29
|
8.033
|
-
|
-
|
-
|
Free Cash Flow
1 |
35.87
|
-1.553
|
51.34
|
319
|
49.96
|
73.3
|
FCF margin
|
57.5%
|
-9.23%
|
61.16%
|
68%
|
35.86%
|
57.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
157.76%
|
-
|
128.57%
|
74.59%
|
60.83%
|
73.12%
|
Dividend per Share
|
-
|
-
|
-
|
6.000
|
-
|
-
|
Announcement Date
|
6/14/18
|
6/21/19
|
6/25/20
|
6/21/21
|
6/16/22
|
11/1/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
140
|
26.6
|
68.7
|
114
|
159
|
257
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
35.9
|
-1.55
|
51.3
|
319
|
50
|
73.3
|
ROE (net income / shareholders' equity)
|
14%
|
-88.7%
|
45%
|
334%
|
43.5%
|
35.8%
|
ROA (Net income/ Total Assets)
|
10%
|
1.89%
|
10.9%
|
53.9%
|
12.5%
|
11.1%
|
Assets
1 |
227.2
|
-5,684
|
367.2
|
792.8
|
657.5
|
906
|
Book Value Per Share
2 |
36.10
|
13.80
|
21.70
|
-
|
-
|
-
|
Cash Flow per Share
2 |
0.8300
|
2.700
|
0.6200
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/14/18
|
6/21/19
|
6/25/20
|
6/21/21
|
6/16/22
|
11/1/23
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 19.08M | | -40.31% | 8.15B | | +8.65% | 3.6B | | -0.25% | 2.27B | | -24.56% | 1.9B | | -18.21% | 1.72B | | +5.95% | 922M | | +16.75% | 731M | | -10.48% | 679M | | -0.60% | 288M |
Bio Diagnostics & Testing
|